查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070460

2026 年至 2034 年脂肪肝疾病藥物的市場規模、佔有率、成長、全球產業分析、區域趨勢和預測。

Fatty Liver Disease Drugs Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

脂肪肝疾病藥物市場的成長要素

2025年，全球脂肪肝疾病（STAD）藥物市場規模達9.834億美元。預計該市場將從2026年的16.2億美元成長至2034年的91.941億美元，預測期內複合年成長率（CAGR）為24.24%。這一強勁成長反映了市場正從研發管線主導階段轉向早期商業化階段，而這主要得益於診斷率的提高以及已通過核准治療代謝紊亂相關性脂肪性肝炎（MASH）的療法的日益普及。

此市場指的是為脂肪肝患者（尤其是伴隨中度至進行性纖維化的MASH患者）所開發的藥物治療方案。這些治療方案包括口服和注射藥物，其作用標靶包括代謝路徑、發炎和纖維化進展。肥胖率上升、非侵入性診斷工具的改進以及醫療專業人員意識提升，正顯著推動市場滲透。

關鍵促進因素包括全球肥胖和糖尿病負擔日益加重、肝纖維化盛行率上升、疾病篩檢水準提高以及新核准療法的臨床應用日益廣泛。緩解疾病、肝功能提升和標靶代謝效應等益處進一步推動了市場成長。此外，強勁的研發投入和不斷擴充的產品線也在加速創新。

主要公司包括 Madrigal Pharmaceuticals、Novo Nordisk、Boehringer Ingelheim、Achero Therapeutics、Inventiva、Viking Therapeutics 和 AltoImmune，所有這些公司都專注於基於 GLP-1 療法、THR-BETA促效劑和 FGF21 的藥物開發策略。

市場占有率

到 2025 年，由於肥胖症盛行率高以及能夠較早獲得已通過核准的治療方法，北美將主導市場。

到 2025 年，THR-BETA促效劑細分市場佔了最大的市場佔有率，這得益於首個獲批的口服 MASH 療法的廣泛應用。

由於口服給藥方式方便，且有醫師的大力支持，因此口服給藥方式在市場上佔領先地位。

區域展望

北美地區在全球脂肪肝藥物市場佔領先地位，這主要歸功於該地區脂肪肝疾病的高發病率、完善的診斷體係以及品牌療法的早期商業化。美國憑藉其快速的藥物分銷管道和完善的醫保報銷體系，佔了該市場的大部分佔有率。

在歐洲，預計肝病治療市場將出現顯著成長，這得益於人們對肝病認知的提高以及肝病診療路徑的擴展。亞太地區預計將成為成長最快的地區，這主要受中國、印度和日本龐大的患者群體以及代謝性疾病發病率上升的推動。在世界其他地區，隨著醫療服務可近性的提高，治療方法也逐漸普及。

市場促進因素

其中一個主要因素是全球肥胖負擔日益加重，這直接導致脂肪肝和MASH（主要不良心血管事件）的發生率上升。這導致需要標靶藥物治療的患者群體不斷擴大，而僅靠生活方式管理是不夠的。

另一個重要的促進因素是利用非侵入性纖維化檢測方法來提高診斷能力。早期發現患者顯著增加了符合治療條件的患者數量，從而推動了對已通過核准療法和在研療法的需求。

市場限制因素

由於MASH的複雜性，在纖維化的各個階段實現一致的治療效果十分困難，臨床試驗的高失敗率仍然是一個主要的阻礙因素。這增加了研發成本並延緩了產品核准。

市場機遇

透過聯合治療和策略聯盟拓展產品線蘊藏著巨大的機會。製藥公司之間的合作能夠加速藥物研發，並拓展疾病各階段的治療選擇，進而提升商業性潛力。

市場挑戰

由於纖維化改善和長期治療效果的核准要求不斷變化，監管方面的不確定性構成了一項重大挑戰。這導致研發週期延長，並使全球商業化策略更加複雜。

細分分析

副產品

Rezdiffra（瑞美羅）作為首個獲準的專門用於治療MASH的藥物，自上市以來一直佔市場主導地位，並展現出強勁的商業性前景。 Wegovy（Semaglutide）因其適應症擴展至代謝紊亂和肥胖症，成為成長最快的細分市場。

藥物類別

THR-BETA促效劑因其肝臟特異性作用機制和已證實的臨床療效而佔市場主導地位。 GLP-1受體促效劑因其對肥胖和代謝調節的雙重作用，成為成長最快的細分市場。

透過行政途徑

由於口服給藥途徑方便、患者遵守用藥性高且易於長期使用，因此佔市場主導地位。而注射給藥途徑則在開發平臺中先進注射用生物製藥的推動下快速成長。

透過分銷管道

由於需要事先核准、保險報銷支援和病患管理項目，專科藥局佔了市場主導地位。隨著藥品供應量的增加，零售藥局也穩定成長。

馬德里加爾製藥公司

諾和諾德

勃林格殷格翰國際股份有限公司

Inventiva

維京治療公司

阿爾托伊穆納

Akero Therapeutics

89bio（F.霍夫曼拉羅氏有限公司）

產業趨勢

2026 年：AltoImmune 公司憑藉 pembidutide 治療 MASH 獲得了 FDA 的突破性療法認定。

2026 年：EMA 的人用藥品委員會對Semaglutide治療非肝硬化 MASH 表示了正面的看法。

2025年：羅氏收購89bio，以加強其MASH產品線。

2025 年：Madrigal 擴大了其口服 GLP-1 製劑的全球授權協議。

2025 年：Altimmune 公司公佈了 MASH 的 2b 期臨床試驗的正面結果。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 大型公司管道分析
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 主要國家和地區的監管趨勢

第5章：2021-2034年全球脂肪肝疾病藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品分類。
    • Rezdiffra（Resmetirom）
    • Wegovy（Semaglutide）
    • 其他
  • 市場分析、洞察與預測：按藥物類別分類
    • THR-BETA促效劑
    • GLP-1受體促效劑
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥局和藥房
    • 專科藥房及其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美脂肪肝疾病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲脂肪肝疾病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第8章：亞太地區脂肪肝疾病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他亞太國家

第9章：2021-2034年世界其他地區脂肪肝藥物市場分析、洞察與預測

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Madrigal Pharmaceuticals, Inc.
    • Novo Nordisk
    • F. Hoffmann-La Roche Ltd（89bio, Inc.）
    • Inventiva
    • Boehringer Ingelheim International GmbH
    • Viking Therapeutics
    • Altimmune
Product Code: FBI116006

Growth Factors of fatty liver disease drugs Market

The global fatty liver disease drugs market was valued at USD 983.4 million in 2025. The market is projected to grow from USD 1,620.0 million in 2026 to USD 9,194.1 million by 2034, exhibiting a CAGR of 24.24% during the forecast period. The strong expansion reflects the transition of the market from a pipeline-driven stage to early commercialization, supported by increasing diagnosis rates and growing availability of approved therapies for metabolic dysfunction-associated steatohepatitis (MASH).

The market refers to pharmaceutical treatments developed for fatty liver disease, particularly MASH patients with moderate to advanced fibrosis. These therapies include oral and injectable drugs targeting metabolic pathways, inflammation, and fibrosis progression. Rising obesity rates, improved non-invasive diagnostic tools, and increasing awareness among healthcare providers are significantly driving market adoption.

Key drivers include the rising global burden of obesity and diabetes, increasing prevalence of liver fibrosis, improved disease screening, and expanding clinical adoption of newly approved therapies. Benefits such as disease modification, improved liver function, and targeted metabolic action further support market growth. Additionally, strong R&D investments and expanding drug pipelines are accelerating innovation.

Major players include Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Akero Therapeutics, Inventiva, Viking Therapeutics, and Altimmune, focusing on GLP-1 therapies, THR-beta agonists, and FGF21-based drug development strategies.

Market Share

North America dominated the market in 2025 due to high obesity prevalence and early access to approved therapies.

The THR-beta agonist segment held the largest share in 2025, driven by strong adoption of first approved oral MASH therapy.

The oral route of administration segment dominated due to convenience and strong physician preference.

REGIONAL OUTLOOK

North America leads the global fatty liver disease drugs market due to high disease prevalence, strong diagnostic infrastructure, and early commercialization of branded therapies. The U.S. contributes the majority share due to rapid drug adoption and strong reimbursement systems.

Europe is expected to grow significantly, supported by increasing awareness of liver diseases and expanding hepatology care pathways. Asia Pacific is projected to register the fastest growth due to a large patient population and rising metabolic disorders across China, India, and Japan. The Rest of the World is witnessing gradual adoption supported by improving healthcare access.

MARKET DRIVERS

A major driver is the rising global obesity burden, which directly increases the incidence of fatty liver disease and MASH. This expands the patient pool requiring targeted pharmaceutical intervention beyond lifestyle management.

Another key driver is improved diagnostic capability using non-invasive fibrosis detection methods. Early identification of patients has significantly increased treatment eligibility, driving demand for approved and pipeline therapies.

MARKET RESTRAINTS

High clinical trial failure rates remain a key restraint due to the complex nature of MASH, where achieving consistent treatment outcomes across fibrosis stages is challenging. This increases development costs and delays product approvals.

MARKET OPPORTUNITIES

Strong opportunities exist in combination therapies and pipeline expansion through strategic collaborations. Partnerships between pharmaceutical companies are accelerating drug development and expanding treatment options across different disease stages, improving commercial potential.

MARKET CHALLENGES

Regulatory uncertainty is a major challenge as approval requirements for fibrosis improvement and long-term outcomes continue to evolve. This increases development timelines and complicates global commercialization strategies.

SEGMENTATION ANALYSIS

By Product

Rezdiffra (resmetirom) dominates the market as the first approved MASH-specific therapy with strong early commercial uptake. Wegovy (semaglutide) is the fastest-growing segment due to expanding metabolic and obesity-related applications.

By Drug Class

THR-beta agonists lead the market due to liver-specific mechanisms and strong clinical validation. GLP-1 receptor agonists are the fastest growing due to their dual benefits in obesity and metabolic regulation.

By Route of Administration

The oral segment dominates due to convenience, better patient compliance, and ease of long-term use. The parenteral segment is growing rapidly due to advanced injectable biologics in development pipelines.

By Distribution Channel

Specialty pharmacies dominate due to the need for prior authorization, reimbursement support, and patient management programs. Retail pharmacies are growing steadily with broader drug availability.

COMPETITIVE LANDSCAPE

The market is moderately consolidated, with Madrigal Pharmaceuticals leading due to early approval and strong commercial rollout of Rezdiffra. Novo Nordisk is strengthening its position through GLP-1 based therapies, while other players are focusing on pipeline expansion and strategic partnerships. Competition is intensifying as multiple late-stage candidates move toward commercialization.

LIST OF KEY COMPANIES

Madrigal Pharmaceuticals, Inc.

Novo Nordisk

Boehringer Ingelheim International GmbH

Inventiva

Viking Therapeutics

Altimmune

Akero Therapeutics

89bio (F. Hoffmann-La Roche Ltd)

INDUSTRY DEVELOPMENTS

2026: Altimmune received FDA Breakthrough Therapy Designation for pemvidutide in MASH.

2026: EMA CHMP issued positive opinion for semaglutide in non-cirrhotic MASH.

2025: Roche acquired 89bio to strengthen its MASH pipeline.

2025: Madrigal expanded global licensing agreements for oral GLP-1 assets.

2025: Altimmune reported positive Phase 2b MASH clinical results.

CONCLUSION

The global fatty liver disease drugs market is expected to grow rapidly from USD 983.4 million in 2025 to USD 1,620.0 million in 2026 and reach USD 9,194.1 million by 2034. The market growth is driven by rising obesity prevalence, increasing diagnosis of MASH, and rapid commercialization of new drug therapies. Strong pipeline development, expanding approvals, and strategic collaborations are further strengthening long-term growth prospects. With increasing clinical adoption and innovation in metabolic and liver-targeted therapies, the market is expected to witness strong and sustained expansion throughout the forecast period.

Segmentation By Product, Drug Class, Route of Administration, Distribution Channel, and Region

By Product * Rezdiffra (Resmetirom)

  • Wegovy (Semaglutide)
  • Others

By Drug Class * THR-beta Agonist

  • GLP-1 Receptor Agonist
  • Others

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Specialty Pharmacies & Others

By Region * North America (By Product, Drug Class, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Product, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Product, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Product, Drug Class, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Rezdiffra (Resmetirom)
    • 5.1.2. Wegovy (Semaglutide)
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. THR-beta Agonist
    • 5.2.2. GLP-1 Receptor Agonist
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Specialty Pharmacies & Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Rezdiffra (Resmetirom)
    • 6.1.2. Wegovy (Semaglutide)
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. THR-beta Agonist
    • 6.2.2. GLP-1 Receptor Agonist
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Specialty Pharmacies & Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Rezdiffra (Resmetirom)
    • 7.1.2. Wegovy (Semaglutide)
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. THR-beta Agonist
    • 7.2.2. GLP-1 Receptor Agonist
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Specialty Pharmacies & Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Rest of Europe

8. Asia Pacific Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Rezdiffra (Resmetirom)
    • 8.1.2. Wegovy (Semaglutide)
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. THR-beta Agonist
    • 8.2.2. GLP-1 Receptor Agonist
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Specialty Pharmacies & Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Rest of Asia Pacific

9. Rest of the World Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Rezdiffra (Resmetirom)
    • 9.1.2. Wegovy (Semaglutide)
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. THR-beta Agonist
    • 9.2.2. GLP-1 Receptor Agonist
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Specialty Pharmacies & Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Madrigal Pharmaceuticals, Inc.
    • 10.2.2. Novo Nordisk
    • 10.2.3. F. Hoffmann-La Roche Ltd (89bio, Inc.)
    • 10.2.4. Inventiva
    • 10.2.5. Boehringer Ingelheim International GmbH
    • 10.2.6. Viking Therapeutics
    • 10.2.7. Altimmune

List of Tables

  • Figure 1: Global Fatty Liver Disease Drugs Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034
  • Figure 2: Global Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025 & 2034
  • Figure 3: Global Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 4: Global Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 5: Global Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Fatty Liver Disease Drugs Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034
  • Figure 8: North America Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025
  • Figure 9: North America Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034
  • Figure 10: North America Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 11: North America Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034
  • Figure 12: North America Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 13: North America Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Fatty Liver Disease Drugs Market Value (USD million), by Country, 2025 & 2034
  • Figure 16: North America Fatty Liver Disease Drugs Market Value Share (%), by Country, 2025
  • Figure 17: Europe Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034
  • Figure 18: Europe Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025
  • Figure 19: Europe Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034
  • Figure 20: Europe Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 21: Europe Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034
  • Figure 22: Europe Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 23: Europe Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Fatty Liver Disease Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Fatty Liver Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034
  • Figure 28: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025
  • Figure 29: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034
  • Figure 30: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 31: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 33: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Fatty Liver Disease Drugs Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Fatty Liver Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Product, 2025 & 2034
  • Figure 38: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Product, 2025
  • Figure 39: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Drug Class, 2025 & 2034
  • Figure 40: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 41: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Route of Administration, 2025 & 2034
  • Figure 42: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 43: Rest of the World Fatty Liver Disease Drugs Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 44: Rest of the World Fatty Liver Disease Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Global Fatty Liver Disease Drugs Market Share (%), by Company, 2025